Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05457218 · ClinicalTrials.gov registry record · NA
Effect of Insect-derived Protein Supplements on Protein Synthesis and mTORC1 Activation
A NA study of Effect of Food Supplement, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05457218: Completed NA study of Effect of Food Supplement, sponsored by University of California, Davis.
NCT05457218 is a NA study of Effect of Food Supplement that has completed, run by University of California, Davis. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05457218, a NA study of Effect of Food Supplement, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the ability of insect-derived protein supplements (IPC80 and Whole Buffalo Powder Ynsect®) to activate the mTORC1 pathway and protein synthesis in muscle cells. To achieve this aim, participants will consume a supplemental dose (0.25 g/kg body weight) of IPC80,Whole Buffalo Powder or whey protein. Blood samples will be drawn before and 15, 30, 60 and 90 minutes after the supplementation. Protein synthesis will be assessed using stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) and to determine the ability of a protein source to activate mTORC1, stably transfected C2C12 muscle cells with a plasmid (pcDNA3-TOP luciferase) where the luciferase mRNA contains a 5'TOP. 5'TOP which is specifically regulated by mTORC1 activity will be used.
Primary Outcome
To measure muscle protein synthesis, stably transfected C2C12 muscle cells with a plasmid (pcDNA3 luciferase) will be used. C2C12Luc cells will be plated in 24-well plates and differentiated over 4 days. Differentiated C2C12 cells will be fasted by washing with PBS and then treating them with Test Media (20% DMEM) for 15 minutes. Fasted muscle cells will then be treated with Test Media containing 0, 2.5, 5, or 10% baseline or fed serum (from blood samples at 15, 30, 60, and 90 minutes after supp
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Whey protein
- DIETARY_SUPPLEMENT IPC80
- DIETARY_SUPPLEMENT Whole Buffalo Powder
Study Locations (1)
California
- Hickey Laboratory - Davis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
What the finished NCT05457218 record still lists
NCT05457218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Effect of Food Supplement appearing as the primary indexed condition, and to 3 interventions - of which Whey protein is the first listed.
NCT05457218 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05457218 about?
NCT05457218 is a clinical study titled "Effect of Insect-derived Protein Supplements on Protein Synthesis and mTORC1 Activation". The purpose of this study is to determine the ability of insect-derived protein supplements (IPC80 and Whole Buffalo Powder Ynsect®) to activate the mTORC1 pathway and protein synthesis in muscle cells. To achieve this aim, participants will consume a supplemental dose (0.25 g/kg body weight) of IP...
What is the current status of trial NCT05457218?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2022-10-01. Estimated completion is 2024-09-30.
What conditions does trial NCT05457218 study?
This clinical trial studies the following conditions: Effect of Food Supplement.
What interventions are being tested in trial NCT05457218?
The interventions under investigation include: Whey protein (DIETARY_SUPPLEMENT), IPC80 (DIETARY_SUPPLEMENT), Whole Buffalo Powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05457218?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05457218 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05457218's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI